Meeting
2021 ASCO Annual Meeting
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
Presenter
Michael J. Morris, MD
Memorial Sloan Kettering Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT03574571
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5091)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5091
Abstract #
TPS5091
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2020 ASCO Virtual Scientific Program
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
Speaker: Michael J. Morris, MD
Videos & Slides
2023 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.
Speaker: Daniel P. Petrylak, MD
Videos & Slides
2016 ASCO Annual Meeting
Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).
Speaker: A. Oliver Sartor, MD
Videos & Slides
2013 ASCO Annual Meeting
Aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC): results from a multinational phase 3 trial (VENICE)
Speaker: Ian Tannock, MD, PhD, FRCPC, DSc